Prostate-specific membrane antigen (PSMA), which is highly expressed in prostate adenocarcinoma, was discovered in the 1990s and has been an attractive target for both imaging and therapy [189]. This evidence concerns the gene FOLH1 and prostate adenocarcinoma.